Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

revvity inc. - RVTY

RVTY

Close Chg Chg %
99.49 2.10 2.11%

Closed Market

101.59

+2.10 (2.11%)

Volume: 1.46M

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Trade Now

Company Overview: revvity inc. - RVTY

RVTY Key Data

Open

$98.99

 Day Range

98.69 - 102.29

52 Week Range

81.36 - 120.38

 Market Cap

$11.77B

Shares Outstanding

113.38M

 Public Float

112.86M

Beta

1.07

 Rev. Per Employee

N/A

P/E Ratio

48.37

 EPS

$1.22

Yield

28.14%

 Dividend

$0.07

EX-DIVIDEND DATE

Jan 16, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.64M

  

RVTY Performance

1 Week
 
 -8.53%
 
1 Month
 
 -4.70%
 
3 Months
 
 9.63%
 
1 Year
 
 -16.27%
 
5 Years
 
 -31.38%
 

RVTY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About revvity inc. - RVTY

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

RVTY At a Glance

Revvity, Inc.
77 Citypoint 4th Avenue
Waltham, Massachusetts 02451
Phone 1-781-663-6900 Revenue 2.86B
Industry Medical Specialties Net Income 239.88M
Sector Health Technology 2025 Sales Growth 3.667%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

RVTY Valuation

P/E Current 48.372
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 47.20
Price to Sales Ratio 3.964
Price to Book Ratio N/A
Price to Cash Flow Ratio 19.46
Enterprise Value to EBITDA 18.073
Enterprise Value to Sales 4.822
Total Debt to Enterprise Value 0.245

RVTY Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 3.835
Total Asset Turnover 0.233

RVTY Liquidity

Current Ratio 1.682
Quick Ratio 1.397
Cash Ratio 0.691

RVTY Profitability

Gross Margin 43.024
Operating Margin 12.487
Pretax Margin 9.393
Net Margin 8.399
Return on Assets 1.953
Return on Equity 3.216
Return on Total Capital 2.259
Return on Invested Capital 2.285

RVTY Capital Structure

Total Debt to Total Equity 46.455
Total Debt to Total Capital 31.72
Total Debt to Total Assets 27.68
Long-Term Debt to Equity 38.334
Long-Term Debt to Total Capital 26.174
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Revvity Inc. - RVTY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.31B 2.75B 2.76B 2.86B
Sales Growth
-34.64% -16.95% +0.16% +3.67%
Cost of Goods Sold (COGS) incl D&A
1.55B 1.43B 1.43B 1.63B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
427.00M 431.77M 427.85M 405.34M
Depreciation
56.40M 66.70M 68.47M 69.75M
Amortization of Intangibles
370.60M 365.07M 359.38M 335.59M
COGS Growth
-35.02% -7.91% +0.28% +13.61%
Gross Income
1.76B 1.32B 1.32B 1.23B
Gross Income Growth
-34.30% -24.91% +0.04% -7.10%
Gross Profit Margin
+53.16% +48.07% +48.01% +43.02%
2022 2023 2024 2025 5-year trend
SG&A Expense
979.61M 922.70M 912.14M 872.14M
Research & Development
221.62M 216.58M 196.84M 215.84M
Other SG&A
757.99M 706.12M 715.30M 656.30M
SGA Growth
-20.54% -5.81% -1.14% -4.38%
Other Operating Expense
- - - -
-
Unusual Expense
54.18M 132.85M 55.82M 11.46M
EBIT after Unusual Expense
726.94M 266.64M 354.70M 345.18M
Non Operating Income/Expense
28.85M 15.15M 57.70M 15.28M
Non-Operating Interest Income
3.59M 72.13M 73.19M 31.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
103.95M 98.81M 96.28M 92.19M
Interest Expense Growth
+1.79% -4.95% -2.57% -4.25%
Gross Interest Expense
103.95M 98.81M 96.28M 92.19M
Interest Capitalized
- - - -
-
Pretax Income
651.84M 182.98M 316.13M 268.28M
Pretax Income Growth
-49.07% -71.93% +72.77% -15.14%
Pretax Margin
+19.68% +6.65% +11.47% +9.39%
Income Tax
139.16M 3.47M 33.05M 28.39M
Income Tax - Current - Domestic
- 143.19M 48.98M 59.75M
Income Tax - Current - Foreign
- 101.89M 78.15M 75.54M
Income Tax - Deferred - Domestic
- (61.38M) (80.46M) (45.37M)
Income Tax - Deferred - Foreign
- (44.54M) (43.20M) (56.86M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
512.68M 179.50M 283.07M 239.88M
Minority Interest Expense
- - - -
-
Net Income
512.68M 179.50M 283.07M 239.88M
Net Income Growth
-45.65% -64.99% +57.70% -15.26%
Net Margin Growth
+15.48% +6.53% +10.27% +8.40%
Extraordinaries & Discontinued Operations
- 56.50M (297.88M) 12.76M
Discontinued Operations
- 56.50M (297.88M) 12.76M
Net Income After Extraordinaries
569.18M (118.38M) 295.83M 239.88M
Preferred Dividends
- - - -
-
Net Income Available to Common
569.18M (118.38M) 295.83M 239.88M
EPS (Basic)
- 4.5117 -0.9493 2.4099
EPS (Basic) Growth
- -44.44% -121.04% +353.86%
Basic Shares Outstanding
- 126.16M 124.70M 122.76M
EPS (Diluted)
4.5021 -0.9493 2.4086 2.0574
EPS (Diluted) Growth
-44.31% -121.09% +353.72% -14.58%
Diluted Shares Outstanding
126.43M 124.81M 122.82M 116.59M
EBITDA
1.21B 831.26M 838.37M 761.98M
EBITDA Growth
-33.07% -31.19% +0.86% -9.11%
EBITDA Margin
+36.48% +30.22% +30.43% +26.68%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 114.50
Number of Ratings 22 Current Quarters Estimate 1.026
FY Report Date 03 / 2026 Current Year's Estimate 5.401
Last Quarter’s Earnings 1.70 Median PE on CY Estimate N/A
Year Ago Earnings 5.06 Next Fiscal Year Estimate 5.98
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 19 19 19
Mean Estimate 1.03 1.31 5.40 5.98
High Estimates 1.10 1.42 5.45 6.12
Low Estimate 1.00 1.22 5.30 5.70
Coefficient of Variance 2.34 3.88 0.60 1.62

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 5 7
OVERWEIGHT 5 4 6
HOLD 10 11 7
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Revvity Inc. - RVTY

Date Name Shares Transaction Value
Sep 18, 2025 Anita Gonzales Please See Remarks 4,340 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $82.87 per share 359,655.80
Sep 18, 2025 Maxwell Krakowiak Please See Remarks 12,217 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $82.87 per share 1,012,422.79
Feb 20, 2025 Anita Gonzales Please See Remarks 3,790 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $112.26 per share 425,465.40
Feb 20, 2025 Anita Gonzales Please See Remarks 3,873 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $112.26 per share 434,782.98
Feb 7, 2025 Prahlad Ramadhar Singh Please See Remarks; Director 57,838 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Maxwell Krakowiak Please See Remarks 15,784 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Miriame Victor Please See Remarks 11,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Miriame Victor Please See Remarks 14,288 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Miriame Victor Please See Remarks 10,128 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 1,252,732.32
Feb 7, 2025 Tajinder S. Vohra Please See Remarks 19,345 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 2,392,783.05
Feb 7, 2025 Prahlad Ramadhar Singh Please See Remarks; Director 106,258 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Prahlad Ramadhar Singh Please See Remarks; Director 85,338 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 10,555,457.22
Feb 7, 2025 Joel S. Goldberg Please See Remarks 13,656 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Joel S. Goldberg Please See Remarks 37,689 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Joel S. Goldberg Please See Remarks 32,750 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 4,050,847.50
Feb 7, 2025 Tajinder S. Vohra Please See Remarks 9,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Tajinder S. Vohra Please See Remarks 22,625 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Revvity Inc. in the News